This CME program was derived from content presented at the Clinical Congress of Rheumatology 2018 annual meeting in Destin, Florida. The expert faculty, Drs. Alan L. Epstein and Anthony M. Turkiewicz, will review the pathogenesis of disease as well as joint symptoms for patients with active psoriatic arthritis (PsA). Controversies in the treatment and management of PsA along with rheumatoid arthritis will be outlined. Current and emerging trial data in PsA will be analyzed, comparing traditional monotherapies to combination therapies. The faculty will discuss the algorithm TNFi versus IL-17i in the context of clinical decision making when treating patients with psoriatic arthritis in practice. Strategies for implementing a tailored approach to managing PsA and the associated comorbidities will be relayed. After completing of this CME program, learners will gain insight into current best practices for treating and managing the PsA paint population.
Rheumatologists and other health care providers that are involved in the management of psoriatic arthritis
1. Review differences in the pathogenesis of psoriatic arthritis
2. Evaluate controversies in the treatment and management of rheumatoid arthritis and psoriatic arthritis
3. Discuss strategies for patient assessment and early diagnosis of psoriatic arthritis
4. Analyze recent clinical trial data for the treatment and management of PsA
5. Apply the most up-to-date science to improve outcomes in PsA patients
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Alan L. Epstein, MD||Speaker’s Bureau: AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech Inc.; Janssen Pharmaceuticals, Inc.; Lilly USA, LLC; Novartis AG.; Pfizer, Inc.; Quest Pharmaceuticals Inc.; Sanofi, Genzyme and Regeneron Pharmaceuticals|
|Anthony M. Turkiewicz, MD||Consultant/Advisor: AbbVie, Inc.; Lilly USA, LLC Novartis AGGrant/Research Support: AbbVie, Inc.; Janssen Pharmaceuticals, Inc.; Lilly USA, LLC; Novartis AG.; Pfizer, Inc.; Sanofi, Genzyme and Regeneron Pharmaceuticals; UCB, Inc. Speaker’s Bureau: AbbVie, Inc.; Janssen Pharmaceuticals, Inc.; Lilly USA, LLC; Novartis AG; Pfizer, Inc.; Sanofi, Genzyme and Regeneron Pharmaceuticals; UCB, Inc.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Lilly USA, LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Lilly USA, LLC do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].